Company intelligence / Profile preview

Alexis Bio

Boston, Massachusetts, United Statesalexisbioenergy.com ↗

Ownership: Private
Development stage: Other

Overview

Alexis Bio’s lead product, realSKIN™, is the first live cell xenotransplant to receive FDA RMAT designation. It is in Phase 3 trials evaluating its ability to provide complete and durable wound closure from a single application in severe burn patients. The RMAT status allows for increased regulatory interaction and potential accelerated approval pathways. No final clinical results have been published yet.

Therapeutic areas: Dermatology
Modalities: Genetically engineered cell therapies (xenotransplantation)Live cell xenotransplants (e.g., realSKIN)
Industry: Biotech

Drug pipeline

1 asset

realSKIN

Partnerships

XenoTherapeutics

Beyond the preview

Go deeper on Alexis Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alexis Bio.

Explore the full profile